Session » RA – Diagnosis, Manifestations, and Outcomes Poster I

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0267

Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register

1:00PM-3:00PM: Abstract Number: 0246

Comorbidity Clusters in Patients with Rheumatoid Arthritis Predict Survival Prognosis

1:00PM-3:00PM: Abstract Number: 0263

DAS28 (disease Activity Score) Elevations in Patients with Rheumatoid Arthritis (RA) Who Have Comorbid Fibromyalgia Are Explained by Elevated Tender Joint Counts as Much as by Elevated Patient Global Assessment

1:00PM-3:00PM: Abstract Number: 0253

Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic

1:00PM-3:00PM: Abstract Number: 0266

Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression

1:00PM-3:00PM: Abstract Number: 0257

High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory

1:00PM-3:00PM: Abstract Number: 0249

Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease

1:00PM-3:00PM: Abstract Number: 0244

Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab

1:00PM-3:00PM: Abstract Number: 0259

Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA

1:00PM-3:00PM: Abstract Number: 0260

Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 0265

In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases

1:00PM-3:00PM: Abstract Number: 0241

Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients

1:00PM-3:00PM: Abstract Number: 0245

Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD

1:00PM-3:00PM: Abstract Number: 0255

Is Abatacept as Effective and Safe in Rheumatoid Arthritis Patients with Previous Malignancy as in Those Without?

1:00PM-3:00PM: Abstract Number: 0254

Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial

1:00PM-3:00PM: Abstract Number: 0270

Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 0261

Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans

1:00PM-3:00PM: Abstract Number: 0252

Mitochondrial Content in Skeletal Muscle of Individuals with Rheumatoid Arthritis Is Associated with Physical Activity Level

1:00PM-3:00PM: Abstract Number: 0248

Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA

1:00PM-3:00PM: Abstract Number: 0242

Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging

1:00PM-3:00PM: Abstract Number: 0251

Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 0256

Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires

1:00PM-3:00PM: Abstract Number: 0250

Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina

1:00PM-3:00PM: Abstract Number: 0269

Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage

1:00PM-3:00PM: Abstract Number: 0262

Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study

1:00PM-3:00PM: Abstract Number: 0243

Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study

1:00PM-3:00PM: Abstract Number: 0264

Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis

1:00PM-3:00PM: Abstract Number: 0247

Rheumatoid Arthritis as a Modifier of the Cognition-Daily Function Association

1:00PM-3:00PM: Abstract Number: 0258

Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents

1:00PM-3:00PM: Abstract Number: 0268

Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry

1:00PM-3:00PM: Abstract Number: 0271

Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A Nationwide Population-based Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].